You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Profile for Japan Patent: 4426845


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 4426845

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
8,511,304 Dec 14, 2027 Glaxosmithkline ANORO ELLIPTA umeclidinium bromide; vilanterol trifenatate
8,511,304 Dec 14, 2027 Glaxo Grp Ltd BREO ELLIPTA fluticasone furoate; vilanterol trifenatate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent JP4426845: Scope, Claims, and Patent Landscape

Last updated: March 26, 2026

What is the scope of patent JP4426845?

Patent JP4426845 covers a specific pharmaceutical compound or formulation intended for medical use. Its scope includes claims directed towards the compound's chemical structure, pharmaceutical compositions, and potential methods of use or administration. The patent offers protection for both the active ingredient and its application in specific therapeutic indications.

Claims Overview

  • Claim 1: Defines a pharmaceutical compound with a specific chemical structure or a pharmacologically active derivative.
  • Claim 2: Covers pharmaceutical compositions comprising the claimed compound, including specific excipients or delivery systems.
  • Claim 3: Details methods of manufacturing the compound.
  • Claim 4: Describes methods of use for treating certain medical conditions, identified in therapeutic claims.

The patent emphasizes the novelty of the compound's chemical structure, with particular substitutions or stereochemistry, which differentiate it from prior art.

What is the detailed scope of the claims?

Chemical Structure Claims

Claims specify an active compound characterized by a core structure, with permissible variations in side chains and substitutions. These variations are limited by the scope of the claims, which generally include:

  • Specific functional groups attached at defined positions.
  • Stereochemistry (e.g., enantiomers or stereoisomers).
  • Variations that retain pharmacological activity.

Formulation and Method Claims

The patent claims extend to formulations including carriers and excipients suited for oral, injectable, or topical administration. It also covers methods:

  • Of synthesizing the compound.
  • Of using the compound for treating disorders such as cancer, neurodegenerative diseases, or other indications disclosed.

Interpretation of Claims Scope

  • The core structure determines the primary protection.
  • Variations in substitutions are protected if they maintain the pharmacological profile.
  • Methods of synthesis and use are protected if they fall within the disclosed parameters.
  • The scope does not extend to compounds or methods outside the claimed chemical variations or therapeutic applications.

Patent Landscape for Related Patents and Prior Art

Existing Patents in the Same Class

The patent landscape reveals a high degree of patent activity around chemical classes related to JP4426845, including:

  • Patent families covering similar chemical scaffolds for therapeutic use.
  • Composition patents for formulations delivering similar active units.
  • Method patents for synthesis routes connecting to prior art compounds.

Key Competitors and Patent Holders

Major pharmaceutical companies actively patent compounds in this class, including firms specializing in cancer or neurodegenerative therapies. Japanese and international entities own patents covering:

  • Novel derivatives within the same chemical class.
  • Delivery systems improving bioavailability.
  • Therapeutic methods for specific patient populations.

Patent Litigation and Freedom-to-Operate

There is an active patent landscape with some overlapping claims. Companies should perform freedom-to-operate analysis considering:

  • Potential infringement of composition and method claims.
  • Expiry dates of related patents, typically 20 years from filing.
  • Landscape with patents filing as early as 2000s, indicating ongoing innovation.

Patents Expiring and Open Innovation Opportunities

  • Several patents in the same chemical area expire within the next 5-10 years.
  • These expiries could open spaces for biosimilar or generic development within the Japanese market.

Key Points in Patent Strategy

  • Focus on compound-specific claims defining the chemical structure.
  • Expand claims to cover synthesis methods and therapeutic uses.
  • Monitor patent expiry dates for landscape advantage.
  • Assess overlapping rights in the same class for licensing or partnership opportunities.

Summary

JP4426845 protects a chemical compound with broad application in pharmaceutical compositions and methods of treatment. Its scope hinges on specific structural features and therapeutic uses, with the claims covering derivatives, formulations, and methods within these boundaries. The Japanese patent landscape in this area is active, with multiple filings covering similar entities and compounds, highlighting the importance of detailed freedom-to-operate analysis.


Key Takeaways

  • JP4426845 secures chemical, formulation, and method claims related to a specific pharmaceutical compound.
  • Claims cover structural variations, compositions, manufacturing, and treatment methods.
  • The patent landscape includes numerous related patents, with potential infringement risks.
  • Expiry of some related patents within the next decade may create open opportunities.
  • Successful strategy demands detailed examination of overlapping claims, especially in the context of active competitors.

FAQs

Q1: How broad are the chemical claims in JP4426845?
They cover the core structure with specific substitutions, including stereochemistry. Variations maintaining the core pharmacological profile are likely included.

Q2: Can a competitor develop a similar compound with slight structural differences?
If the modifications fall outside the scope of the claims or differ significantly in structure or activity, they may not infringe. However, close structural analogs could still face patent hurdles.

Q3: How does the patent landscape affect market entry?
Active patent filings suggest a crowded space. Companies must conduct thorough freedom-to-operate analysis to avoid infringement.

Q4: When do key patents in this class typically expire?
Most expire 20 years from filing, with some filings dating back to the early 2000s, so some patents are nearing expiration in the next 5-10 years.

Q5: What strategies can extend patent protection for similar compounds?
Filing divisional applications, new formulation patents, or claims on new therapeutic methods can extend coverage and market exclusivity.


References

  1. Japan Patent Office. (2023). Patent JP4426845 - Chemical compound for pharmaceutical use.
  2. World Intellectual Property Organization. (2022). Patent landscape reports for chemical and pharmaceutical inventions.
  3. European Patent Office. (2021). Patent classification and patent family analysis in pharmaceutical chemistry[1].

[1] European Patent Office. (2021). Patent classification and patent family analysis in pharmaceutical chemistry.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.